Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. As of October 6, 2023, Horizon Therapeutics Public Limited Company operates as a subsidiary of Amgen Inc..
तुलना करने के लिए मीट्रिक्स | HZNP | पीअर्स समकक्ष - बारीकी से मेल खाने वाली कंपनियों से संबंधित मेट्रिक्स का औसत HZNP: | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधHZNPपीअर्सक्षेत्र |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | 0.0x | 0.0x | |
PEG अनुपात | 0.00 | 0.00 | 0.00 | |
क़ीमत/बुक | 0.0x | 0.0x | 0.0x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 0.0x | 0.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 0.0% | 0.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.0% | 0.0% | अनलॉक करें |